阿尔茨海默病的眼部生物标志物:通过眼部诊断进行早期检测的启示--文献综述。

Q2 Medicine
G Firmani, M Salducci, F Testa, G P Covelli, P Sagnelli, A Lambiase
{"title":"阿尔茨海默病的眼部生物标志物:通过眼部诊断进行早期检测的启示--文献综述。","authors":"G Firmani, M Salducci, F Testa, G P Covelli, P Sagnelli, A Lambiase","doi":"10.7417/CT.2024.5125","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Alzheimer's Disease (AD) is a significant challenge in neurodegenerative disorders, characterized by a gradual decline in cognitive functions. Diagnosis typically occurs at advanced stages when therapeutic options are less effective, underscoring the importance of early detection. Traditional diagnostic methods are often invasive and costly, spurring interest in more accessible and economical alternatives. The eye, as a direct link to the brain through the optic nerve, suggests that ocular changes could serve as early indicators of AD. This has led to the exploration of non-invasive ocular diagnostic tools. Technologies such as Optical Coherence Tomography (OCT), OCT Angiography (OCT-A), pupillometry, and eye-tracking, along with electrophysiological methods like Electroretinography (ERG) and Pattern Electroretinography (PEV), are being utilized to investigate potential ocular biomarkers. Further, tear fluid analysis has suggested that presence of amyloid-beta (Aβ) protein might reflect neurogenerative processes, providing a non-invasive window into disease progression. Exploring ocular changes as potential early indicators of Alzhei-mer's Disease (AD), we aimed to provide an overview of promising biomarkers for earlier diagnosis and intervention. Our review further investigates the connections between AD and other ocular degenera-tive diseases such as age-related macular degeneration (AMD) and glaucoma, uncovering shared pathogenic pathways that could offer new therapeutic targets. To establish the sensitivity and specificity of these ocular biomarkers, comprehensive studies are required. Moreover, larger, longitudinal studies are essential to confirm the effectiveness of ocular assessments in the preemptive diagnosis of Alzheimer's Disease.</p>","PeriodicalId":50686,"journal":{"name":"Clinica Terapeutica","volume":"175 5","pages":"352-361"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ocular Biomarkers in Alzheimer's Disease: Insights into Early Detection Through Eye-Based Diagnostics - A Literature Review.\",\"authors\":\"G Firmani, M Salducci, F Testa, G P Covelli, P Sagnelli, A Lambiase\",\"doi\":\"10.7417/CT.2024.5125\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>Alzheimer's Disease (AD) is a significant challenge in neurodegenerative disorders, characterized by a gradual decline in cognitive functions. Diagnosis typically occurs at advanced stages when therapeutic options are less effective, underscoring the importance of early detection. Traditional diagnostic methods are often invasive and costly, spurring interest in more accessible and economical alternatives. The eye, as a direct link to the brain through the optic nerve, suggests that ocular changes could serve as early indicators of AD. This has led to the exploration of non-invasive ocular diagnostic tools. Technologies such as Optical Coherence Tomography (OCT), OCT Angiography (OCT-A), pupillometry, and eye-tracking, along with electrophysiological methods like Electroretinography (ERG) and Pattern Electroretinography (PEV), are being utilized to investigate potential ocular biomarkers. Further, tear fluid analysis has suggested that presence of amyloid-beta (Aβ) protein might reflect neurogenerative processes, providing a non-invasive window into disease progression. Exploring ocular changes as potential early indicators of Alzhei-mer's Disease (AD), we aimed to provide an overview of promising biomarkers for earlier diagnosis and intervention. Our review further investigates the connections between AD and other ocular degenera-tive diseases such as age-related macular degeneration (AMD) and glaucoma, uncovering shared pathogenic pathways that could offer new therapeutic targets. To establish the sensitivity and specificity of these ocular biomarkers, comprehensive studies are required. Moreover, larger, longitudinal studies are essential to confirm the effectiveness of ocular assessments in the preemptive diagnosis of Alzheimer's Disease.</p>\",\"PeriodicalId\":50686,\"journal\":{\"name\":\"Clinica Terapeutica\",\"volume\":\"175 5\",\"pages\":\"352-361\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Terapeutica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7417/CT.2024.5125\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Terapeutica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7417/CT.2024.5125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

摘要:阿尔茨海默病(AD)是神经退行性疾病中的一大难题,其特点是认知功能逐渐衰退。诊断通常发生在治疗效果较差的晚期阶段,这凸显了早期检测的重要性。传统的诊断方法往往是侵入性的,而且成本高昂,这激发了人们对更方便、更经济的替代方法的兴趣。眼睛通过视神经与大脑直接相连,这表明眼部变化可作为注意力缺失症的早期指标。因此,人们开始探索非侵入性的眼部诊断工具。光学相干断层扫描(OCT)、OCT 血管造影(OCT-A)、瞳孔测量、眼球跟踪等技术,以及视网膜电图(ERG)和模式视网膜电图(PEV)等电生理方法,都被用来研究潜在的眼部生物标志物。此外,泪液分析表明,淀粉样蛋白-β(Aβ)的存在可能反映神经变性过程,为了解疾病进展提供了一个非侵入性窗口。作为阿尔茨海默病(AD)的潜在早期指标,我们对眼部变化进行了探索,旨在概述有望用于早期诊断和干预的生物标志物。我们的综述进一步研究了阿尔茨海默病与其他眼部变性疾病(如老年性黄斑变性(AMD)和青光眼)之间的联系,发现了可提供新治疗靶点的共同致病途径。要确定这些眼部生物标志物的敏感性和特异性,需要进行全面的研究。此外,还必须进行更大规模的纵向研究,以确认眼部评估在阿尔茨海默病预防性诊断中的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ocular Biomarkers in Alzheimer's Disease: Insights into Early Detection Through Eye-Based Diagnostics - A Literature Review.

Abstract: Alzheimer's Disease (AD) is a significant challenge in neurodegenerative disorders, characterized by a gradual decline in cognitive functions. Diagnosis typically occurs at advanced stages when therapeutic options are less effective, underscoring the importance of early detection. Traditional diagnostic methods are often invasive and costly, spurring interest in more accessible and economical alternatives. The eye, as a direct link to the brain through the optic nerve, suggests that ocular changes could serve as early indicators of AD. This has led to the exploration of non-invasive ocular diagnostic tools. Technologies such as Optical Coherence Tomography (OCT), OCT Angiography (OCT-A), pupillometry, and eye-tracking, along with electrophysiological methods like Electroretinography (ERG) and Pattern Electroretinography (PEV), are being utilized to investigate potential ocular biomarkers. Further, tear fluid analysis has suggested that presence of amyloid-beta (Aβ) protein might reflect neurogenerative processes, providing a non-invasive window into disease progression. Exploring ocular changes as potential early indicators of Alzhei-mer's Disease (AD), we aimed to provide an overview of promising biomarkers for earlier diagnosis and intervention. Our review further investigates the connections between AD and other ocular degenera-tive diseases such as age-related macular degeneration (AMD) and glaucoma, uncovering shared pathogenic pathways that could offer new therapeutic targets. To establish the sensitivity and specificity of these ocular biomarkers, comprehensive studies are required. Moreover, larger, longitudinal studies are essential to confirm the effectiveness of ocular assessments in the preemptive diagnosis of Alzheimer's Disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinica Terapeutica
Clinica Terapeutica PHARMACOLOGY & PHARMACY-
CiteScore
2.50
自引率
0.00%
发文量
124
审稿时长
6-12 weeks
期刊介绍: La Clinica Terapeutica è una rivista di Clinica e Terapia in Medicina e Chirurgia, fondata nel 1951 dal Prof. Mariano Messini (1901-1980), Direttore dell''Istituto di Idrologia Medica dell''Università di Roma “La Sapienza”. La rivista è pubblicata come “periodico bimestrale” dalla Società Editrice Universo, casa editrice fondata nel 1945 dal Comm. Luigi Pellino. La Clinica Terapeutica è indicizzata su MEDLINE, INDEX MEDICUS, EMBASE/Excerpta Medica.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信